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The extracellular environment of the central nervous system (CNS) becomes highly structured and organized as the nervous system
matures. The extracellular space of the CNS along with its subdomains plays a crucial role in the function and stability of the CNS.
In this review, we have focused on two components of the neuronal extracellular environment, which are important in regulating
CNS plasticity including the extracellular matrix (ECM) and myelin. The ECM consists of chondroitin sulfate proteoglycans
(CSPGs) and tenascins, which are organized into unique structures called perineuronal nets (PNNs). PNNs associate with the
neuronal cell body and proximal dendrites of predominantly parvalbumin-positive interneurons, forming a robust lattice-like
structure. These developmentally regulated structures are maintained in the adult CNS and enhance synaptic stability. After
injury, however, CSPGs and tenascins contribute to the structure of the inhibitory glial scar, which actively prevents axonal
regeneration. Myelin sheaths and mature adult oligodendrocytes, despite their important role in signal conduction in mature
CNS axons, contribute to the inhibitory environment existing after injury. As such, unlike the peripheral nervous system, the
CNS is unable to revert to a “developmental state” to aid neuronal repair. Modulation of these external factors, however, has
been shown to promote growth, regeneration, and functional plasticity after injury. This review will highlight some of the
factors that contribute to or prevent plasticity, sprouting, and axonal regeneration after spinal cord injury.
1. Introduction
Repair of the central nervous system (CNS) after injury is one
of the biggest challenges facing neuroscientists today. The
most common causes of traumatic spinal cord injury (SCI)
are preventable and include road traﬃc accidents, falls, vio-
lence, and contact sports, which often leave individuals with
various types of sensory and/or motor deﬁcits with many los-
ing their independence. Traumatic SCI is more prevalent in
males than females and occurs most commonly in young
adulthood (15–29 years) and also older age (over 60) [1].
Treatment is limited for SCI and often revolves around pre-
venting further damage with interventions involving rehabil-
itation being the current standard of care in the clinic [2].
1.1. ECM and Pathophysiology after CNS/Axonal Injury. The
CNS does not regenerate following injury due to a multitude
of inhibitory factors. Intrinsically, adult central neurons are
limited in their capacity to mount a regenerative response
partly due to the inhibitory environment at the injury site.
Several researchers have demonstrated that there is an initial
growth response following injury; however, once axons
encounter the inhibitory environment within the lesion,
growth is arrested, leaving dystrophic axonal end bulbs in
their place [3–5]. Within the normal CNS, cells are sur-
rounded by an extracellular matrix (ECM) composed of a
complex and interactive network of glycoproteins and pro-
teoglycans [6]. Under various circumstances, these molecules
can either promote neurite outgrowth such as during neuro-
nal development [7] or repel it, such as after injury [8–20] or
during disease/degenerative conditions [21] (Figure 1).
Additionally, one of the main reasons the spinal cord is
resistant to repair is due to the complex and distinctive path-
ophysiology that occurs following injury. The underlying
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Figure 1: Changes in the extracellular environment during development, maturation, and injury. The extracellular environment is modiﬁed
and sculpted during development in an activity- and experience-dependent manner. This gives rise to a mature and reﬁned neuronal network
in adulthood. The somatodendritic (I) and axonal (II) compartments are modiﬁed by diﬀerent molecules and cells in the extracellular
environment. I. (a) During development, ECM molecules such as CSPGs, tenascins, and semaphorins are upregulated. Growth-promoting
factors are also expressed by neurons. These molecules aid synaptic plasticity through sprouting, growth, guidance and formation of new
contacts. (b) As the CNS matures, synapses are pruned and only functionally relevant synapses are retained in adulthood. Components of
the ECM, coalesce, forming PNNs around the cell body and proximal dendrites of neurons. This prevents new synapse formation and
therefore limits plasticity. (c) After CNS injury, the same molecules that promoted growth during development now have inhibitory
eﬀects. CSPGs and semaphorins are upregulated, preventing growth cones forming new synaptic contacts leading to limited sprouting and
plasticity. (d) The continuum of synaptic growth and plasticity increases during development but becomes limited in adulthood and
further inhibited after injury. II. (e) During development, growth cones extend from unmyelinated axons to form new synaptic contacts.
This is mediated by molecules that promote growth such as semaphorins, tenascins, and integrins; thus, plasticity and growth are
favoured. (f) As the CNS matures, (adulthood) oligodendrocytes form mature myelin sheaths containing MAIs (Nogo-A, MAG, and
OMgp), restricting aberrant sprouting. Astrocytes secrete CSPGs to limit structural plasticity. Growth-promoting proteins such as
integrins and their ECM ligands (tenascins) are downregulated and absent in the axon. These factors maintain a stable environment. (g)
After CNS injury, CSPGs and semaphorins are upregulated, preventing new growth cones from connecting to targets, leading to
dystrophic end bulbs. Reactive astrocytes form a glial scar at the site of injury, preventing regeneration of damaged axons. Myelin debris
and MAIs released from damaged myelin sheaths inhibit sprouting, axonal extension, and regeneration. Tenascin is upregulated without a
concomitant upregulation of its growth-promoting integrin receptor, alpha9beta1. As such after injury, the CNS environment is not
conducive to repair and regeneration. (h) The continuum of axonal growth increases during development, becomes stable in adulthood
but is signiﬁcantly impaired/inhibited after injury.
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biology of SCI consists of a primary and a secondary phase.
The primary phase is the initial injury suﬀered upon impact.
This can include pressure on the spine, internal bleeding, as
well as severed axons and nerves. Depending on the type of
injury, the blood-brain barrier (BBB) may become com-
promised resulting in leukocyte inﬁltration [22, 23] as well
as disruption of ionic homeostasis leading to signiﬁcant
changes in calcium (Ca2+) and potassium (K+) concentra-
tions at the injury site [24, 25]. Furthermore, disruption of
blood supply to the injury site can result in inadequate oxy-
gen and nutrient supply to the aﬀected tissue. At this stage,
emergency treatment is required to prevent further damage.
Emergency treatment includes stabilization of the spine often
followed by surgical decompression to reduce the inﬂam-
matory response and prevent any additional bleeding.
Over the subsequent weeks and months, the injury enters
the secondary phase, resulting in progressive neurodegen-
eration. This phase is associated with a second set of
symptoms including inﬂammation, neuronal and glial apo-
ptosis, glutamate excitotoxicity, potential disruption of the
BBB, axonal demyelination, and reactive astrogliosis, lead-
ing to the formation of a glial scar. Together with scar for-
mation, axonal demyelination and Wallerian degeneration
give rise to axonal retraction [26]. Axonal retraction occurs
in two phases: (1) an early axon intrinsic, cytoskeleton-
associated phase, in which Ca2+-dependent activation of
calpain proteases leads to cytoskeletal breakdown [27]
and (2) a macrophage-dependent phase, in which inﬁltra-
tion of phagocytic macrophages induces/correlates with
retraction of dystrophic axons [28]. Alongside this, there
is an upregulation of a number of inhibitory proteins includ-
ing chondroitin sulfate proteoglycans (CSPGs), myelin-
associated inhibitors (MAIs), and chemorepellent proteins
[29]. Furthermore, the immune system reacts after injury
with a concomitant and robust gliosis comprised of micro-
glial, macrophage, and astrocyte activation and upregulation.
The release of cytokines and ECM proteins associated with
this gliosis may modulate the immune response and tissue
damage [29]. Activation of microglia after SCI has been
shown to contribute to the sustained chronic pain often
suﬀered by individuals following injury [30, 31]. Together,
this biological cascade of events not only creates an inhibitory
environment but also eﬀectively reduces axonal plasticity
resulting in failed repair.
A large proportion of ongoing SCI research focuses
on neuroprotection and/or treatment of these secondary
mechanisms. As such, therapeutic strategies targeting
removal or degradation of myelin debris and CSPGs have
shown great promise for CNS repair. In this review, we
will discuss some of the major contributing factors to
the prevention of plasticity, sprouting, and axonal regenera-
tion after SCI.
2. Myelin in the Nervous System
Myelination is an essential and unique feature of the adult
nervous system providing electrical insulation and rapid prop-
agation of action potentials over long distances, as well as met-
abolic support [32]. Oligodendrocytes and Schwann cells are
highly specialized myelin-producing cells of the CNS and
peripheral nervous system (PNS), respectively. Oligodendro-
cytes send out up to about 60 projections from a single cell
body. Schwann cells, in comparison, form a single myelin
internode around one axon. In the CNS, each oligodendro-
cyte projection wraps extensively around a short axonal
segment to form myelin internodes [33]. This is particularly
important for long axons that may be several centimeters or
even meters away from the cell body. The physiological
function and dynamics of oligodendrocytes and myelin have
been reviewed in detail by Saab and Nave [34].
Myelination in the human brain continues over several
decades with the highest volume of white matter relative
to total brain volume peaking in the ﬁfth decade of life
[35]. Interestingly, higher order centres such as the cortex
are myelinated later than less complex regions involved
in basic neurological and homeostatic functions such as
the brainstem.
Myelin is not a static structure but instead is slowly and
continuously modiﬁed/remodelled over time in the healthy
adult nervous system. In the visual cortex of normal aging
rhesus monkeys, internodal length decreases, suggesting
active remyelination occurs throughout life [36]. Indeed,
shorter myelin internodes are also observed in the healthy,
adult mouse during normal aging [37]. Small changes, such
as internodal length, can lead to changes in conduction
speed and signal timing, which is crucial for the proper func-
tion of integrated neuronal circuits [38, 39]. Just as neuronal
activity associated with cognitive and motor tasks stimulates
synaptic plasticity, similar activities have been reported to
stimulate increases in region-dependent myelination [40].
These observations support the plastic nature of the neuro-
glia interaction for function.
Neuron (axon) and oligodendrocyte (myelin) cross talk is
also required to maintain proper metabolic function of
axons. This communication modulates many factors includ-
ing localization of ion channels, cytoskeletal function, and
axonal transport [41–44] and has recently been meticulously
reviewed byMicu and colleagues with regard to axo-myelinic
neurotransmission [45]. Myelination begins during devel-
opment and as such, myelinated axons become dependent
on the support provided by these glial cells [46, 47]. This
dependency has been demonstrated in mice deﬁcient in the
myelin-speciﬁc proteolipid protein (PLP/DM20). Axonal
swellings, associated predominantly with small-diameter
myelinated axons, were observed from the age of 6 to 8 weeks
in these mice [46]. Similarly, mice lacking 2′, 3′-cyclic nucle-
otide phosphodiesterase (CNP) in oligodendrocytes show no
structural abnormality in myelin but develop axonal swell-
ings leading to degeneration in adulthood (from 3.5 months
of age and onwards) [47].
Myelination not only maximizes conduction velocity but
it also controls the temporal resolution of neuronal circuits.
This feature is critical for the precise control of motor, sen-
sory, and cognitive functions. As such, neuronal circuits are
able to adapt and respond to various stimuli and experiences,
underpinning learning and memory. However, the adult
CNS has put in place inhibitory mechanisms and molecules,
such as myelin-associated inhibitors (MAIs), to prevent or
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minimize gross structural plasticity and remodelling that
could be detrimental to the physiological function of the cir-
cuit. Although the precedence for these “protective” mecha-
nisms is understandable for retaining a given network, it
imposes restrictions on plasticity and regeneration after
CNS injury. Interestingly, the situation is somewhat diﬀerent
in the PNS. It has long been accepted that axons within the
PNS are able to regenerate after peripheral nerve damage
[48]. Unlike the CNS, MAIs are either not found or are rap-
idly cleared by glial cells of the PNS. As such, both isolated
Schwann cells and peripheral nerve grafts have been shown
to create a growth-permissive environment following injury
[49–51], emphasizing fundamental diﬀerences that underpin
the capacity of the PNS to promote growth and repair while
providing a stimulatory environment compared to the inhib-
itory environment of the CNS.
2.1. Myelin-Associated Inhibitors (MAIs).Nogo, oligodendro-
cyte myelin glycoprotein (OMgp), andmyelin-associated gly-
coprotein (MAG) have all been identiﬁed as MAIs that are
able to collapse axonal growth cones and inhibit neurite out-
growth [52–56] (Figure 1) (Table 1). Nogo-A, a membrane-
associated protein belonging to the reticulon family [57], is
expressed predominantly in oligodendrocyte cell bodies,
processes, and mature myelin. It is also expressed in several
types of neurons in the developing and adult nervous systems
[58]. Nogo-A was identiﬁed as a neurite growth inhibitor in
the 1980’s [59, 60]. This inhibition was associated with at
least two distinct growth-inhibitory domains, Nogo-66 [61,
62] and Nogo-A-Δ20 [63]. Evidence of the inhibitory eﬀects
of Nogo-A came from in vitro studies in which exposure of
chicken retinal ganglion and rat dorsal root ganglion
(DRG) neurons to Nogo-A was shown to inhibit neurite out-
growth and induce growth cone collapse [54, 64, 65]. Neu-
tralization of Nogo-A allowed axonal growth of cocultured
sensory and sympathetic neurons into optic nerve explants
[60] and induced sprouting of adult rat Purkinje axons
in vivo [66].
The MAI OMgp is also expressed in oligodendrocytes
and in several types of CNS neurons such as pyramidal cells
in the hippocampus and Purkinje cells in the cerebellum
among others [67]. Although less is known about OMgp in
comparison to Nogo-A and MAG, like its counterparts, it
has also been shown to be a potent inhibitor of neurite out-
growth in multiple cell lines and primary neuronal cultures
[56, 68, 69]. Interestingly, OMgp was originally reported to
be localized to the nodes of Ranvier in the CNS and was also
shown to inhibit collateral sprouting [69]. In OMgp knock-
out mice, impairment of CNS nodes was observed, giving
rise to larger nodal lengths and greater sprouting from these
nodes compared to wild-type animals, suggesting that
nodal ensheathment by OMgp is important in CNS myelin
development and axonal plasticity [69]. In a more recent
study, however, anti-OMgp antiserum previously used to
deﬁne the function of OMgp at nodes was shown to be non-
speciﬁc [70]. The antiserum displayed strong cross reactivity
to the CSPG versican V2 and showed no defects in paranodes
or increased nodal collateral sprouting in OMgp-null mice,
potentially refuting the involvement of OMgp in node of
Ranvier assembly or maintenance [70]. Despite these con-
ﬂicting reports, the importance of OMgp in development
and maturation of CNS myelination was shown in knockout
mice that presented with hypomyelination and impaired
conduction velocities in their spinal cords [71].
MAG, another MAI [52, 72, 73], is a minor component of
mature, compact myelin, enriched in the periaxonal mem-
brane of the myelin sheath and is expressed by oligodendro-
cytes and Schwann cells. Initially MAG was thought to
promote neurite outgrowth [74]; however, in studies investi-
gating its interaction with primary neurons, the opposite
eﬀect was observed. As such, puriﬁed recombinant MAG
was found to block neurite outgrowth as well as induce
growth cone retraction [52, 75]. Furthermore, Chinese ham-
ster ovary (CHO) cells expressing MAG on their surface,
cocultured with 7-day-old rat cerebellar neurons and adult
DRGs, were found to inhibit neurite outgrowth [53]. In
contrast, when embryonic DRG neurons were grown on
MAG-CHO cells, they extended long neurites. These results
highlighted the developmental regulation of neurite out-
growth and the switch to growth inhibition that occurs in
adult/postnatal neurons [53]. The inhibitory properties of
MAG were further conﬁrmed by demonstrating that myelin
from MAG knockout mice was not inhibitory to growth of
DRG neurons in vitro as compared to myelin from normal
mice [76]. Furthermore, inhibition of neurite outgrowth
was completely abolished by immunodepletion of MAG
from the soluble fraction of myelin-conditioned media [77].
These observations suggest that in addition to myelin debris,
soluble MAIs, likely released after injury, can inﬂuence the
growth capacity of neurons and axons.
2.2. Myelin-Associated Plasticity. In addition to the inhibi-
tory role of MAIs on neurite outgrowth, these molecules
have a signiﬁcant inﬂuence in the control of plasticity in
the CNS. In the developing nervous system, Nogo-A
expression is high in many neurons. As such, Nogo-A
has been shown to rapidly modulate actin cytoskeletal
dynamics to control structural plasticity at dendritic spines
of CA3 pyramidal neurons in the hippocampus in vivo
[78]. Nogo-A was also shown to restrict α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor insertion, providing a mechanism by which it can
regulate the strength of excitatory synaptic transmission
[78]. In the cerebellum, Nogo-A expression correlates with
synaptic reﬁnement and development and has also been
shown to negatively regulate dendritic morphology and syn-
aptic transmission [79]. Neuronal Nogo-A in the adult hip-
pocampus has also been shown to restrict physiological
synaptic activity. This was demonstrated through functional
antibody inhibition of Nogo-A or its receptor, Nogo-66
receptor 1 (NgR1), as well as in Nogo-A knockout mice
[80]. Neutralization of Nogo-A and NgR1 resulted in
increased long-term potentiation (LTP) with no change in
long-term depression (LTD) in acute hippocampal slices
from adult mice [80]. NgR1 expression is necessary to sup-
press synaptic turnover in the adult nervous system and to
maintain and stabilize dendritic spines and axonal varicos-
ities in response to Nogo-A and other ligands. In vivo time-
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Table 1: CNS Inhibitors from myelin, proteoglycans, and ECM. This table summarizes the main inhibitors in the CNS originating from
myelin, proteoglycans, and ECM. The table includes some of the inhibitory eﬀects of these molecules in the CNS as well as experimental
interventions utilized and trialed to counteract the inhibition. This table is by all means not exhaustive but does highlight several
inﬂuential studies that have demonstrated inhibition in the CNS and/or ways to counteract it.
Molecule Inhibitory eﬀect
Interventions to
counteract inhibition
References
Myelin-associated inhibitors (MAIs)
Myelin-associated
glycoprotein (MAG)
Inhibits neurite outgrowth MAG KO mice
[52, 53, 72–77, 107, 108]
Induces growth cone retraction
Immunodepletion
of MAG
Nogo-A
Inhibits neurite outgrowth; induces
growth cone collapse
Anti-Nogo A antibody
[54, 55, 57–66,
78–80, 84–87]
Restriction of synaptic plasticity
and learning/memory
[91, 93, 94, 100, 101,
107, 108, 116–118]
Oligodendrocyte myelin
glycoprotein (OMgp)
Inhibits neurite outgrowth
OMgp KO mice [56, 67–71, 84, 107, 108]
Inhibits collateral sprouting
MAI Receptors
Nogo-66 receptor 1 (NgR1)
Inhibits neurite outgrowth;
induces growth cone collapse
NgR1 KO mice
[61, 62, 68, 80–85,
89, 90, 93, 94]
Restriction of synaptic plasticity
and learning/memory
Blocking NgR1 receptor
[102, 103, 105,
106, 112–114]
Paired immunoglobulin-like
receptor B (PirB)
Restriction of ocular dominance
plasticity; inhibits neurite
PirB KO mice
[95, 103, 104]
Outgrowth; induces growth cone collapse Blocking PirB receptor
Sphingolipid 1-phopsphate
receptor 2 (S1PR2)
Inhibits neurite outgrowth;
restriction of synaptic plasticity
Blocking S1PR2 receptor [88]
ECM and glycoproteins
Chondroitin sulfate proteoglycans
(CSPGs—brevican, neurocan,
aggrecan, phosphacan, versican)
Localized to PNNs; restriction
of plasticity through synaptic
ChABC enzyme - removes
CS-GAGs of PNNs
[10, 13–15, 113,
142–144, 155]
Stabilization in mature neurons;
Novel peptide-mimetic
of PTPσ receptor
[159–163, 168–177]
Secreted by reactive astrocytes of glial scar
limits remyelination
Xyloside treatment
(after demyelination)
Link proteins
(Crtl1/Hapln1; Bral2/Hapln4)
Localized to PNNs; restriction
of plasticity through synaptic
stabilization in mature neurons
Crtl1 conditional KO
mice (neurons)
[142, 143, 154]
Hyaluronan
Localized to PNNs; restriction
of plasticity through synaptic
stabilization in mature neurons
Inhibitor not yet tested in CNS [142, 143]
Tenascin-R (TN-R)
Localized to PNNs; restriction
of plasticity through synaptic
stabilization in mature neurons;
TN-R KO mice
[7, 16, 142, 144–146,
155, 182, 183, 186, 187]
Tenascin-C (TN-C)
Creates neuroanatomical boundaries
for growth in development secreted
by reactive astrocytes after injury
TN-C KO mice
[7, 17–19, 155, 179,
180, 183–185]Reexpression of
α9β1 receptor
Semaphorins Axonal guidance/chemorepulsive molecule [188, 190]
Sema 3A
Localized to PNNs; resticition of
plasticity through synaptic
stabilization in mature neurons;
localized to glial scar postinjury
Sema3A inhibitor
(SM-216289)
[147, 189, 191–193]
Sema 3B
Localized to PNNs; restriction
of plasticity through synaptic
stabilization in mature neurons
Inhibitor not yet tested in CNS [147]
Sema 4D
Localized to myelinating
oligodendrocytes in injury
Inhibitor not yet tested in CNS [194]
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lapse imaging in NgR1 knockout mice revealed an increase
in spine dynamics without a change in total spine density
in the somatosensory cortex [81].
Genetic ablation of NgR1 has also been shown to increase
synaptic density in the juvenile hippocampus as well as
increase spine density in primary hippocampal neurons
[82]. Furthermore, in an earlier study using NgR1 knockout
animals, NMDA-receptor-dependent LTD was attenuated
in the Schaﬀer collateral (CA3-CA1) circuit of the hippocam-
pus [83]. Conversely, in hippocampal slices of adult mice,
treatment with soluble Nogo-A (Nogo66) or OMgp sup-
pressed LTP in an NgR1-dependent manner [84]. Anti-
Nogo-A or NgR1 antibody treatment of coronal brain slices
from adult rat containing the primary motor cortex increased
LTP through NgR1 [85]. In vivo application of the anti-
Nogo-A antibody resulted in greater dendritic spine density
and improved motor performance in a forelimb-reaching
task compared to control antibody-treated animals [85].
Importantly, anti-NogoA antibody treatment also demon-
strated that in an uninjured system, inhibition of the Nogo
pathway induced sprouting of CA3 ﬁbers [86]. In a study
by Zemmar and colleagues, mouse lines in which Nogo-A
was knocked out in either oligodendrocytes or neurons
revealed enhanced dendritic branching and spine formation,
suggesting that both sources of Nogo-A contribute to synap-
tic development and plasticity [87].
Recently, the G-protein-coupled receptor for Nogo-A-
Δ20, sphingolipid 1-phosphate receptor 2 (S1PR2), was
discovered. It was shown that Nogo-A-Δ20 binds S1PR2
to mediate its growth-inhibitory eﬀects by signaling
through the G protein G13, leukemia-associated Rho gua-
nine exchange factor (LARG) and RhoA to mediate actin
destabilization and growth cone collapse [88]. Furthermore,
similar to Nogo-A neutralization strategies using antibodies
or knockdown paradigms, inhibition of S1PR2 blocked
Nogo-A-Δ20, thus counteracting Nogo-A-Δ20’s inhibition
of neurite outgrowth and cell spreading. S1PR2 inhibition
also increased hippocampal and cortical LTP, thus modu-
lating synaptic plasticity [88]. These results demonstrate
that MAIs and their receptors are able to antagonize
growth-promoting pathways to modulate synaptic strength
and transmission inﬂuencing synaptic plasticity.
Nogo-A and NgR1 have also been shown to be important
for regulating memory formation and regulating the acquisi-
tion of diﬀerent behavioural tasks [81, 85, 89, 90]. For
example, Karlsson and colleagues demonstrated impaired
locomotor function and novel object recognition in mice
lacking NgR1 [90]. Overexpression of NgR1 impaired spa-
tial learning memory with a reduction in mature spine
density and complexity [90]. Furthermore, the Morris
water maze test of spatial learning also revealed Nogo-A
knockout mice were able to ﬁnd the hidden platform fas-
ter than wild-type animals and had better long-term mem-
ory retention. This improvement in learning performance
correlated with increased dendritic spine density in CA3
apical dendrites [91].
The involvement of MAIs in limiting neuronal plasticity
has also been elegantly demonstrated in the rodent visual sys-
tem. In the juvenile brain, critical periods (CP) of experience-
driven plasticity occur. These are important for the normal
development of the primary visual cortex. As such, visual
experiences during the CP reﬁne the neuronal network of
the visual system enabling the formation of ocular domi-
nance columns in the cortex. At the end of the CP, mature
networks that have been formed are actively maintained,
thus restricting plasticity [92]. In NgR1 and Nogo-A mutant
mice, although plasticity occurs during the CP, it has also
been shown to continue beyond the normal length of the
CP [93, 94]. As a consequence, robust ocular dominance
plasticity associated with monocular deprivation persists
throughout adulthood [93, 94]. Similarly, ocular dominance
plasticity was extended in the mouse knockout of the MAI
receptor known as paired immunoglobulin-like receptor B
(PirB) [95]. These studies demonstrate that MAIs and
their receptors stabilize the neuronal circuit and limit
experience-driven neuronal plasticity. Thus, MAIs like many
other proteins are involved in consolidation and closure of
CPs through stabilization of mature, highly tuned, and elab-
orate neuronal networks.
2.3. Combatting Myelin Inhibition to Promote Neurite
Outgrowth and Axonal Regeneration. As discussed, myelin
contains several growth-inhibitory molecules that limit both
plasticity and axonal regeneration in the injured mammalian
CNS (Table 1), several of which have been extensively
reviewed elsewhere [34, 96, 97]. A number of strategies to
counteract and neutralize the eﬀects of MAIs starting with
complete demyelination have shown improvements for axo-
nal regeneration and functional recovery. Studies from
Keirstead and colleagues in the 1990’s showed that following
complete or partial demyelination, in and proximal to the
lesion site, promoted axonal regeneration with extensive
neurite outgrowth [98, 99]. Speciﬁcally, after a lateral hemi-
section of the adult rat spinal cord, transient disruption of
mature myelin by intraspinal fusion of serum complement
proteins and a myelin-speciﬁc antibody (anti-galactocereb-
roside, the major sphingolipid in myelin) was shown to facil-
itate axonal regeneration of rubrospinal axons into the
caudal lumbar spinal cord [98]. Using a similar anti-
myelin approach, Keirstead and colleagues demonstrated
that demyelination induced by antigalactocerebroside and
complement, combined with Schwann cell transplantation,
enhanced axonal regeneration following injury [99]. Simi-
larly, in studies aimed at blocking Nogo-A activity with
anti-Nogo-A antibodies, there was signiﬁcantly increased
regeneration and sprouting of transected corticospinal tract
(CST) axons in rats after spinal cord lesion compared to
controls [100, 101]. Additionally, anti-Nogo-A treatment
promoted compensatory ﬁber sprouting and innervation
from the uninjured side to the denervated side [100].
In studies targeting MAI receptors, there have been
several promising studies enhancing neurite outgrowth
and axonal regeneration upon modulation of these receptors.
The NgR1 receptor lacks a transmembrane domain and
therefore forms a complex with other transmembrane co-
receptors such as LINGO-1 (LRR and Ig-containing Nogo
receptor-interacting protein) and p75NTR (p75 neutrotro-
phin receptor) or TROY (tumor necrosis factor receptor
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superfamily member). In doing so, it can transduce the mye-
lin inhibitory signal to the axon, thus mediating growth cone
collapse and growth arrest of neurites [102]. Remarkably, all
three MAIs bind to and activate the same NgR1 receptor
complex [61, 68, 103]. All three MAIs also bind to the PirB
receptor [103]. Blocking either NgR1 or the PirB receptor
partially attenuates growth cone collapse and neurite out-
growth in DRG and cerebellar granule neurons in the pres-
ence of MAIs or myelin. However, in NgR1 null cerebellar
neurons, antibody-mediated PirB inhibition suppressed the
inhibitory eﬀects of MAIs on neurite outgrowth [103]. In
vivo, PirB is reported to play a key role in cortical plasticity
[95]. In contrast to in vitro observations, CST regeneration
was not enhanced in PirB-knockout mice after SCI [104]. A
number of other genetic deletion/mutation studies of MAIs
and their receptors have provided further evidence regarding
the inhibitory action of these proteins on growth. However,
eﬀects after injury in NgR1 or Nogo-A, MAG and OMgp
knockout mice have been variable [105–107]. In triple
mutant mice (Nogo-A, MAG, and OMgp), greater axonal
growth and sprouting of CST and raphespinal tract axons
and improved locomotion were observed after SCI compared
to single or double knockouts [108]. However, Lee and
colleagues observed limited axonal sprouting and regenera-
tion of CST axons after SCI with no synergistic eﬀects in tri-
ple knockout animals [107]. This variability may likely be due
to the location and type of injury as well as compensation and
synergism between MAIs and other growth-inhibitory fac-
tors in single knockout animals. Indeed, growth-inhibitory
molecules such as EphrinA3, signaling via the EphrinA4
receptor, are upregulated in the spinal cord of Nogo-A
knockout mice, thus suggesting that compensatory mecha-
nisms mediate the residual inhibition observed in these
animals to restrict neurite outgrowth and repair [109].
Combatting myelin inhibition with other treatment strat-
egies including vaccines, monoclonal antibodies (including
the anti-Nogo A antibody), and peptide ligands to compete
for receptor binding [62, 110] have shown signiﬁcant poten-
tial for CNS repair [111]. After either acute or chronic SCI in
rodents, treatment with a soluble NgR1 decoy protein
(NgR1(310) ecto-Fc) that neutralizes the eﬀects of all three
MAIs (Nogo-A, MAG, and OMgp) has shown promising
results in promoting axonal sprouting and functional recov-
ery [112–114]. Interestingly, after a spinal dorsal column
crush injury in adult rats, inclusion of either a preconditioning
peripheral sciatic nerve lesion and application of NgR1 decoy
protein treatment or Chondroitinase ABC (ChABC—an
enzyme which digests the glycosaminoglycan sugar chains of
CSPGs) treatment led to greater axonal regeneration [115].
Combining two of these treatments did not enhance regener-
ation any further; however, combining all three promoted
axons to regenerate millimeters past the lesion site [115].
Acute antibody blockade of Nogo-A alone has been
shown to enhance axon sprouting in the injured spinal cord
as well as improve behavioural outcomes [100, 101, 116]. In
a rat model of stroke, anti-Nogo-A antibody treatment
increased dendritic arborization and spine density [117].
Similar treatments have also resulted in increased sprouting
and ﬁber regeneration after lesion in rat organotypic
hippocampal slice cultures [86]. Antibodies against Nogo-A
delivered via injection of hybridoma cells producing IN-1
antibody (raised against an inhibitory fraction of myelin)
into the frontoparietal cortex 7–10 days prior to the spinal
cord lesion promoted regeneration of axons up to 7–11mm
in transected CST axons within 2–3 weeks postinjury [116].
In a complimentary study, adult rats implanted with IN-1-
secreting hybridomas in the hippocampus immediately after
dorsal overhemisection of the spinal cord showed greater
improvements in locomotor function [101]. A study using
intrathecal administration of anti-Nogo-A antibodies into
the subdural space also induced regeneration of CST axons
alongside behavioural improvements in open ﬁeld loco-
motion, ladder walking, narrow beam walking, as well as
improvements in response to heat and von Frey hairs [100].
Due to the successful regeneration observed in experimental
injury models treated with anti-Nogo-A antibodies as
described above, clinical trials are now underway using these
antibodies for the treatment of stroke and SCI [111, 118].
2.4. Remyelination after Injury. Despite the multitude of
inhibitory factors associated with myelin, replacement of oli-
godendrocytes and myelin around demyelinated axons is
thought to be a key mechanism in promoting CNS regenera-
tion, with the aim of reinstating neuron-glia cross talk and
functional recovery. Mature oligodendrocytes, like neurons,
are postmitotic cells and therefore do not contribute to
remyelination after injury. Remyelination is established pre-
dominately by proliferating oligodendrocyte precursor cells
(OPCs) expressing platelet-derived growth factor receptor
A, neuron-glial antigen 2 (NG2) cells, but also neural stem
and progenitor cells (NSPCs). These cells migrate to the
lesion site where they diﬀerentiate and give rise to adult-
born, myelinating oligodendrocytes following injury [119–
122]. This robust oligodendrogenesis occurs throughout
the ﬁrst few months after injury, which partially compensates
for loss of mature oligodendrocyte and myelin [123]. Newly
formed oligodendrocytes have been shown to generate mye-
lin sheaths in a short space of time [124]. As such, plastic
changes associated with de- and remyelination are possible.
Indeed, genetic ablation of new myelin-forming oligoden-
drocytes impairs performance on a complex wheel motor
task in mice [125].
MAIs and other growth-limiting proteins are impor-
tant for maintaining physiological plasticity and neuronal
network stability. Unfortunately, this eﬀectively restricts/
prevents surviving neurons/networks from re-establishing
functional connectivity after injury or disease. The impor-
tance of myelination for the function of the CNS has been
described earlier and it is therefore understandable that after
injury, where axonal degeneration and demyelination occur,
spontaneous remyelination also occurs to stabilize vulnerable
axons [126, 127]. However, similar to the inadequate axonal
regeneration that occurs following injury, the extent and
quality of remyelination is also thought to be inadequate,
resulting in incomplete, abnormally thin myelin sheaths
and continued axonal dysfunction [128, 129].
Many studies have reported a high prevalence of very
thin myelin surrounding lesion zones even years after SCI.
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In adult rats, incomplete myelination was reported up to
450 days following contusive SCI [130]. In postmortem
chronically injured human spinal cords, 1–22 years fol-
lowing injury, immunohistochemical analysis also demon-
strated some axonal demyelination even a decade
following SCI [131].
Experimentally, after a chronic contusive SCI, the major-
ity of spared rubrospinal axons are demyelinated in rats [132]
and mice [133]. By measuring spared rubrospinal axons that
traverse the injury site with shortened internodal lengths
(indicative of remyelination), it was found that the majority
of spared axons were remyelinated by 3 months after SCI
[132]. Hesp and colleagues also demonstrated remyelination
of spared axons 2–3 months after contusive SCI, albeit ste-
reotypically shorter and thinner, suggesting remyelination
occurs continuously and chronically after SCI [123]. In a sub-
sequent study, Powers and colleagues measured spontane-
ously regenerated myelin in vivo [120]. Consistent with
previous studies, they found that early after injury, the mean
length of regenerated myelin sheaths was signiﬁcantly
shorter than in uninjured myelin; however, by 6 months
post-injury, the newly formed myelin sheaths and internodes
were similar to controls [120]. These studies suggest that
abnormally thin and shorter myelin internodes observed
many months post-injury/pathology may be due to ongoing
demyelination and not incomplete myelin regeneration to
intact spared axons.
Spontaneous remyelination after SCI is slower and less
eﬃcient than remyelination following chemically-induced
focal demyelination. In mice, after lysolecithin-mediated
focal demyelination, myelin debris is rapidly cleared within
the ﬁrst 4 days [134], remyelination is observed at 7 days
and is complete by 3 weeks [135]. The rate of remyelination
after SCI is likely due to the inhibitory environment and
resultant pathology including myelin debris and associated
MAIs (NogoA, MAG, and OMgp) which are themselves
inhibitory to OPC diﬀerentiation [136, 137]. It is clear that
the interplay of demyelination and compensatory remyeli-
nation postinjury is important for functional recovery.
Several sources of myelinating cells have been examined
as transplantation-based therapies for SCI [4, 138, 139].
Such treatments have led to improvements in behavioural
recovery after contusion SCI [140].
Like OPCs, neural progenitor cells also become activated
and migrate to the site of injury. However, they predomi-
nantly diﬀerentiate into reactive astrocytes [121, 122, 129].
This migration of cells contributes to the inhibitory environ-
ment produced by MAIs in and around the glial scar follow-
ing SCI, thus precluding axonal regeneration [141]. In
addition to targeting MAIs as a barrier to neuroregeneration
after injury, other molecules such as components of the
ECM, which work synergistically to maintain a stable, pre-
dominantly growth-inhibitory environment also need to be
considered and are discussed in subsequent sections.
3. CSPGs and Perineuronal Nets
The ECM of the CNS is rich in CSPGs, some existing within
the extracellular milieu and others associated with speciﬁc
structures. Within the CNS, CSPGs can associate into spe-
cialized structures termed perineuronal nets (PNNs) which
surround the soma and dendrites of mature neurons. PNNs
are comprised of ECM proteins including hyaluronan, link-
ing proteins [e.g., cartilage link protein 1 (Crtl1/Hapln1)
and brain-speciﬁc link protein (Bral2/Hapln4)], CSPGs,
and tenascin-R (TN-R) [142], with one further study also
identifying tenascin-C (TN-C) by immunoblot within PNNs
[143] (Figure 1) (Table 1). There are also a number of
CSPGs, including brevican, neurocan, aggrecan, phospha-
can, and versican, which bind to the hyaluronan backbone
of the PNN (Table 1) [144]. Hyaluronan is synthesized by
hyaluronan synthases (HAS). Its interaction with CSPGs
occurs via link proteins (e.g., Hapln1). TN-R molecules
function to cross-link CSPGs to form an organized PNN
backbone. Additionally, TN-R has been shown to interact
with integrins, such as β1 integrins, contactin/F3/F11,
phosphacan, and MAG [145–147]. Recently, semaphorin
3A (sema3A) and 3B (sema3B) (discussed below) have also
been found to be associated with the CSPGs within the
PNN structure [148].
Although PNNs have been localized to some gluta-
matergic neurons in the CNS [149], they predominantly
associate with the neuronal cell body and proximal dendrites
of fast-spiking parvalbumin-positive GABAergic interneu-
rons, forming a robust lattice-like structure [144, 150].
Maintenance of this specialized structure is important for
synaptic and network stabilization and homeostasis. Spe-
ciﬁcally, PNNs function to stabilize mature neurons by
reducing dendritic spine plasticity [151], forming a scaﬀold
for synaptic inhibitory molecules [152], and also restricting
the movement of receptors at the synapse [153]. Forma-
tion and maturation of PNNs is concurrent with the
development and maturation of the nervous system during
CPs. Enzymatic digestion of this specialized ECM struc-
ture with ChABC prolongs the CP in the visual system
[154]. When speciﬁc components of PNNs are deleted,
such as link protein 1 (Crtl1), PNN formation is reduced
and neuronal plasticity is enhanced [155]. Furthermore,
primary neuronal and astrocytic cultures from quadruple
knockout mice that lack the CSPGs neurocan, brevican,
as well as TN-C and TN-R have reduced PNN formation.
In these cases, the mice display changes in synaptic plas-
ticity, impaired synaptogenesis, synapse stability, and
altered synaptic activity [156].
3.1. The Glial Scar and Associated Inhibitory Proteins. As dis-
cussed above, unlike the PNS, the adult mammalian CNS has
a reduced ability to regenerate. This is partly as a result of the
formation of a characteristic glial scar created at the injury
site which surrounds the lesion with reactive astrocytes and
ﬁbroblasts and inhibits axonal regeneration [29]. Further-
more, it has been shown by Davies and colleagues that when
glial scarring is minimized, robust CNS regeneration can
occur even in areas of degenerated white matter in the spinal
cord [157, 158].
CSPGs are the main family of inhibitory proteins asso-
ciated with the glial scar and axonal injury [8–10]. These
include the subgroup lecticans (comprising aggrecan,
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brevican, versican, and neurocan), small leucine-rich pro-
teoglycans (including biglycan and decorin), phosphacan/
receptor-type-protein-tyrosine phosphatase β (RPTPβ),
and other proteoglycans, including NG2 and neuroglycan-
C [159]. After injury, CSPGs are actively secreted into the
ECM, mainly by reactive astrocytes and neurons [160], but
with a minor component also coming from secretion by mac-
rophages and oligodendrocytes [145, 161, 162]. This leads to
an abundance of CSPGs at the injury site, adding to the
inhibitory milieu. The main feature contributing to the inhib-
itory nature of CSPGs is their structure as they have a num-
ber of glycosaminoglycan (GAG) side chains. Each CSPG
varies on the number of side chains they have; for example,
aggrecan contains over 100 GAG side chains while others
contain less than 10 [159]. The number of chains and the
sulfation status of CSPGs equates to the functional eﬀect of
the CSPGs on CNS growth [10, 163–165].
CSPGs impose inhibitory eﬀects on both oligodendro-
cytes and neurons. This has been shown to be mediated
through the protein tyrosine phosphatase sigma (PTPσ)
receptor. When CSPGs bind PTPσ receptors, they initiate
activation of the GTPase Rho/ROCK signaling pathway. In
neurons, this results in an inhibition of axonal growth, con-
verting growth cones into a dystrophic state [13–15]. Using
a novel peptide mimetic of PTPσ, Lang and colleagues were
able to block CSPG-mediated inhibition in vitro, enabling
adult sensory neurons to extend axons through a CSPG
gradient [15]. This was equivalent to ChABC treatment,
which removes the GAG sugar chains containing the PTPσ
ligand. Administration of the PTPσ peptide mimetic after
contusive SCI also facilitated functional recovery of both
locomotor and urinary systems, suggesting reconnection
of functional circuits [15]. When the PTPσ receptor is not
present, animal models of SCI show increased regeneration
of CST axons [166]. This was evidenced through RNAi-
mediated downregulation of PTPσ, which negated the inhib-
itory eﬀects of CSPGs on oligodendrocyte process outgrowth
and myelination. The same eﬀect was observed in oligoden-
drocytes isolated from PTPσ knockout mice [167]. Together,
these results highlight the inhibitory role of CSPGs on OPC
migration, maturation, and myelination, limiting their repar-
ative potential after injury.
Interestingly and contrary to the widely accepted
demonstration of glial scar-mediated inhibition of axon
regeneration, recent evidence by the Sofroniew lab has shown
that the glial scar has a beneﬁcial eﬀect for regrowth and not
only acts a barrier to prevent further damage but also may be
advantageous or at least necessary for the repair process. Spe-
ciﬁcally, in a 2016 study by Anderson and colleagues examin-
ing spinal cord repair in two diﬀerent transgenic mouse
models with reduced glial scar formation either via deletion
of scar-forming astrocytes (TK+GCV; thymidine kinase +
ganciclovir) or via conditional knockout of STAT3 (signal
transducer and activator of transcription 3) speciﬁcally in
astrocytes, they did not ﬁnd an increase in regeneration,
and in some axonal tracts (CST and ascending sensory
tracts), there was an increase in axonal dieback after injury
[168]. Despite acting as a physical barrier to axonal regrowth,
results from this study suggests that the glial scar
modulates the inﬂammatory response after injury and that
without the glial scar present, this inﬂammatory response
can be an equivalent barrier to regrowth [168]. Neverthe-
less, a recent study characterizing the varying phenotypes
of astrocytes speciﬁcally in regard to a lesion site was pub-
lished in 2017 by Hara and coworkers [169]. In this study,
three distinct subtypes of astrocytes associated with the
glial scar were characterized: the naïve astrocytes present
prior to lesion, the reactive astrocytes which are ﬁrst to inﬁl-
trate the lesion milieu and are classiﬁed as “transitional” with
potential neuroprotective and immune-regulatory roles, and
the scar-forming astrocytes which comprise the late stage
growth-inhibitory astrocytic scar [169]. Intriguingly, when
the “transitional” (reactive) astrocytes were transplanted into
naïve spinal cord, they reverted to naïve astrocytes; likewise,
they converted to scar-forming astrocytes when transplanted
into an injury site, demonstrating that the environment
dictates astrocytic phenotype and consequently glial scar-
mediated inhibition [169]. This phenotypic change was
found to largely be controlled by collagen type I found
in high levels within the lesion and shown to be integrin-N-
cadherin-dependent [169]. Without intervention, the normal
fate of astrocytes in close proximity to a CNS lesion is
directed to the scar-forming astrocytic phenotype, which
indeed is detrimental to axonal regeneration. A recent com-
mentary by Silver on glial scar-mediated inhibition and the
inability for mammalian lesions to form growth-promoting
astroglial bridges or to otherwise enhance glial-mediated
regrowth articulates this issue and further elucidates the need
for treatments to counteract the glial scar [170] such as with
ChABC or others.
Enzymatic inactivation of CSPGs by ChABC renders
them unable to interact with their receptors. This has been
shown to be eﬀective in promoting axonal plasticity and
regeneration in many models of SCI. Speciﬁcally, following
a cervical dorsal column lesion and treatment with ChABC,
dorsal column and CST ﬁber growth extended beyond the
injury compared to control, untreated groups where the
axons retracted away from the lesion [171]. In this study,
ChABC also promoted sensory and proprioceptive behav-
ioural recovery after injury [171]. Furthermore, in studies
combining ChABC treatment with forelimb rehabilitation
after dorsal column crush lesion, signiﬁcant axonal regenera-
tion and behavioural recovery also resulted when treated at
the time of injury [172] or with delayed treatment 4 weeks
post-injury [113]. In a rat model of compressive SCI, treat-
ment with ChABC promoted oligodendrocyte diﬀerentiation
and myelination of endogenous and transplanted neural pre-
cursor cells [173, 174]. ChABC treatment also promoted
migration of OPCs in and around the lesion site following a
spinal contusion injury [175]. The inhibitory activities of
CSPGs on OPC diﬀerentiation and myelination have also
been counteracted with small molecules such as protamine,
a heparin antagonist [176].
The presence of CSPGs in and around the lesion site after
SCI as well as in multiple sclerosis has been found to nega-
tively correlate with successful remyelination. In vivo and
in vitro observations show that CSPGs limit migration and
maturation of OPCs. In models of demyelination, lesion-
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induced CSPG upregulation reduced diﬀerentiation and pro-
cess development of OPCs. Clearance of CSPGs by xyloside
treatment after lysolecithin-induced demyelination not only
increased the number of OPCs and oligodendrocytes present
in the lesion site but also signiﬁcantly improved remyelina-
tion [177]. Upregulation of NG2, a CSPG found on the sur-
face of OPCs, was also observed after lysolecithin-induced
demyelination. Remyelination and repair only occurred after
removal of NG2 deposits from the lesion site, mediated by
matrix metalloproteinase-9 [178].
Because ChABC is an enzyme, it has its limitations;
primarily degradation over time [163] and therefore requires
repeated dosing to maintain adequate enzymatic activity to
promote repair. In response to this requirement, long-term
expression of ChABC has been achieved in rat models of
SCI using lentivirus or adeno-associated virus [179], pro-
moting regeneration of CST axons [180]. It is unclear,
however, whether constitutive expression of ChABC over
a long period of time may result in unwanted plasticity
within the CNS.
3.2. Tenascin-C-Mediated Inhibition of CNS Plasticity and
Axonal Regeneration. Alongside increased levels of CSPGs,
there are a number of developmental proteins that are upreg-
ulated after axonal injury in the mature CNS, including
tenascins, semaphorins, ephrins, and netrins [181]. In this
review, we will discuss the role of tenascins and semaphorins
in axonal growth and regeneration. Tenascins are extracellu-
lar glycoproteins that form a constituent part of the ECM
[182]. TN-C is the most abundant glycoprotein within the
CNS ECM, which is highly expressed during development
but is downregulated as the mammalian CNS matures.
TN-C has vastly opposing roles in both the developing
and mature CNS, acting as a growth-promoting molecule
in certain circumstances and a growth-inhibitory molecule
in others. For example, in the developing CNS, these pro-
teins, speciﬁcally TN-C, promote neural precursor prolifera-
tion and migration along with axonal extension, guidance,
and growth cone formation [7]. On the other hand, the pat-
tern of TN-C immunostaining in the developing CNS dem-
onstrates that it can also be inhibitory to growth as it
contributes to the formation of boundaries between neuroan-
atomical subdivisions, showing its chemorepulsive role [183].
Upon injury in the mature CNS, TN-C is upregulated
and deposited in the ECM by reactive astrocytes, contribut-
ing to the inhibitory glial scar that forms after SCI (Table 1)
[11, 12, 16–20]. Conversely, levels of TN-R are increased as
the mammalian CNS matures due to the increased forma-
tion of PNNs as discussed above [184]. Generally, TN-C
exerts an inhibitory eﬀect on mature axons; however,
when bound to a speciﬁc heterodimeric integrin receptor,
alpha9 beta1 integrin (α9β1), which is also downregulated
in the mature CNS, TN-C can promote neurite outgrowth
and axon regeneration [17, 19]. Unfortunately in the mature
CNS, a concomitant upregulation of its integrin receptor
α9β1 does not occur. Integrins, such as the α9β1 heterodi-
mer, are highly expressed during CNS development at the
axonal cell surface to aid growth cone formation and axonal
elongation. The imbalanced upregulation of TN-C after
injury without expression of its growth-promoting receptor
has been shown to substantially contribute to the intrinsic
failure of axonal regeneration. Similar to the situation during
CNS development, TN-C (speciﬁcally the ﬁbronectin III
binding domain, fnD) has also an opposing role in that it
has been shown to be necessary for regeneration [18]. Specif-
ically, spinal cord compression lesion in adult mice led to
more pronounced dying back of severed CST axons in
TN-C knockout mice, which was rescued upon replacement
of TN-C via viral-mediated overexpression of fnD [18].
Both the growth-promoting and inhibitory eﬀects of TN-
C and TN-R have been elucidated in a number of studies.
Interestingly, TN-C and TN-R exert opposite functions in
facial nerve injury. Speciﬁcally, recovery of vibrissal move-
ment was worse in TN-C deﬁcient mice and better in TN-R
deﬁcient mice compared to controls [185]. Single knockout
studies of TN-R and TN-C show impaired LTP and plasticity
in vivo and in vitro [186, 187]. TN-C deﬁcient animals
subjected to hemisection in the lumbar spinal cord showed
increased numbers of neuroﬁlament-positive ﬁbers along
the hemisected edges of the spinal cord [188]. In contrast,
deﬁciency of TN-R improves functional recovery of mice
after compression of the thoracic spinal cord [189] with
further studies using antibodies against TN-R showing
improved recovery following SCI [190].
3.3. Semaphorin-Mediated Inhibition of CNS Plasticity and
Axonal Regeneration. Semaphorins are a class of
membrane-associated proteins involved in axonal growth,
guidance, and formation of new synaptic connections dur-
ing embryonic development [191]. Semaphorins are also
expressed within the adult CNS. In addition, studies of
PNNs have demonstrated that the semaphorins sema3A
and 3B are associated with the CSPGs in PNN structures
suggesting that these semaphorins contribute inhibition
and/or chemorepulsion of axon growth in part by their con-
tribution to PNNs [148]. Speciﬁcally, sema3A was localized
to Wisteria ﬂoribunda agglutinin- (WFA-) positive PNNs,
an association that was eliminated following treatment with
ChABC [148]. Semaphorins have also been detected within
the glial scar post-injury (Table 1) [192–194]. Speciﬁcally,
Sema3A is found to be upregulated after CNS injury [192]
and has likewise been linked to the prevention of regenera-
tion after SCI [195, 196]. In addition, an inhibitor of sema3A,
SM-216289, has been shown to promote axonal regeneration,
enhance Schwann cell migration to the lesion site, inhibit
apoptosis, and signiﬁcantly improve functional recovery of
the hindlimb following transection of the spinal cord in adult
rats [195]. Interestingly, particular semaphorin subtypes, such
as sema4D, have also been found within the membrane of
myelinating oligodendrocytes [197]. Furthermore, after CNS
injury, sema4D is upregulated and can prevent axonal growth
in vitro, suggesting it may contribute to themyelin-associated
inhibitory environment at the lesion site in vivo [197].
4. Summary
Understanding the physiological regulation of axonal growth
and plasticity in the adult nervous system is essential to the
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development of therapeutic strategies. Plasticity and regener-
ation in the CNS, or lack thereof, are heavily regulated by
ECM formation. As the CNS matures, giving rise to myelin-
ated axons, PNNs, and associated proteins, it is reasonable to
understand why there is a reduced capacity for plastic
changes and axonal repair (summarized in Figure 1). These
extraneuronal components are key to maintaining the cir-
cuitry required for normal nervous system function both at
the level of the cell soma and dendrites as well as the axons.
As such, the CNS has protective measures in place to prevent
or limit new axonal growth and/or connections so that
mature networks are not compromised. It is therefore detri-
mental for the CNS to allow axonal growth and plasticity
(at a gross level) to continue throughout adulthood, outside
of normal synaptic plasticity. It is clear from the literature,
however, that the CNS is capable of mounting a regenerative
response if inhibitory factors are (a) removed, creating a
growth-permissive environment or (b) temporally regulated
providing a suﬃcient window for regeneration to occur. By
continuing to understand changes that promote plasticity
and aid repair in the PNS as well as those that prevent repair
in the CNS, we can therefore assess key targets for therapeu-
tic intervention. Going forward, it is highly unlikely that a
single target therapeutic strategy will be successful in fully
promoting both axonal regeneration and behavioural/func-
tional recovery after SCI. Approaches which confront issues
with both the extracellular environment of the CNS together
with the internal environment of the neuron have the best
opportunity for achieving successful repair.
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